BiotechTube
Inreda Diabetic

Inreda Diabetic

Goor, Netherlands· Est.
inredadiabetic.nl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.5M

Overview

Inreda Diabetic is a pioneering private company in the metabolic device sector, focused on a fully closed-loop artificial pancreas system. Its core technology, the Inreda AP®, differentiates itself by using a dual-hormone (insulin and glucagon) approach to automate blood glucose management. The company has progressed to a commercial stage in the Netherlands, with over 100 users, and recently published significant long-term clinical data in The Lancet Digital Health. Inreda represents a advanced, though niche, contender in the growing automated insulin delivery market.

Metabolic DiseaseType 1 Diabetes

Technology Platform

Bi-hormonal (insulin & glucagon) fully closed-loop algorithm and integrated device system for automated blood glucose management.

Funding History

2
Total raised:$6.5M
Series A$5M
Seed$1.5M

Opportunities

The strong clinical data from a large-scale, year-long study published in a leading journal provides powerful validation to drive adoption and reimbursement discussions.
The bi-hormonal approach addresses an unmet need for fully automated control, positioning Inreda as a premium solution in a growing AID market and making it a potential acquisition target.

Risk Factors

The company faces intense competition from larger, well-established players with broader commercial footprints.
The complexity and likely higher cost of a dual-hormone system presents significant market access and reimbursement challenges.
Scaling globally requires substantial capital and regulatory expertise that may strain a small private company.

Competitive Landscape

Inreda competes in the Automated Insulin Delivery (AID) market against major players like Medtronic (MiniMed 780G), Tandem Diabetes Care (t:slim X2 with Control-IQ), and Insulet (Omnipod 5). Its primary differentiation is the bi-hormonal (glucagon) capability, which is only pursued by one other significant competitor, Beta Bionics (iLet). It is a niche, technology-focused challenger against commercial giants.

More companies in Digital Health & Biotech SaaS →More companies in Netherlands →